The present specification teaches a protocol for pain management including a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol comprises the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.
